Rocket Pharma ( (RCKT) ) has released its Q3 earnings. Here is a breakdown of the information Rocket Pharma presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing genetic therapies for rare and complex disorders, utilizing both adeno-associated viral (AAV) vector-based and lentiviral (LV) vector-based platforms. In its latest earnings report for the quarter ended September 30, 2025, Rocket Pharma reported no revenue and a net loss of $50.3 million, reflecting ongoing investments in research and development. The company’s cash and cash equivalents decreased significantly from $163.6 million at the end of 2024 to $75.9 million, as it continues to fund its clinical programs. Key financial metrics include a total operating expense of $52.2 million for the quarter, with research and development expenses accounting for $34.1 million. The company has implemented a strategic reorganization to focus on its highest-priority programs, particularly its AAV-based gene therapy platform for cardiovascular diseases. Looking ahead, Rocket Pharmaceuticals plans to continue its focus on advancing its pipeline and expects its current resources to fund operations into the second quarter of 2027, while it explores additional funding options to support its long-term strategic objectives.